Lipoprotein(a) : new insights into an atherogenic lipoprotein

The Clinical Investigator

Volumn 72, Issue 8, 1994, Pages 558-567

  Bartens, W ^a   Wanner, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Atherosclerosis; Cholesterol; Diabetes mellitus; Dialysis; Nephrotic syndrome

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; CYCLOSPORIN; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

ATHEROSCLEROSIS; DIABETES MELLITUS; HEMODIALYSIS; HUMAN; METABOLISM; NEPHROTIC SYNDROME; REVIEW;

ARTERIOSCLEROSIS; CELL DIVISION; CHROMOSOMES, HUMAN, PAIR 6; DIABETES MELLITUS; DISEASE SUSCEPTIBILITY; ESTROGENS; FEMALE; HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASES; KRINGLES; LIPOPROTEIN(A); MALE; MUSCLE, SMOOTH, VASCULAR; PHENOTYPE; PLASMINOGEN; PREGNANCY; RISK; TRANSFORMING GROWTH FACTOR BETA;

EID: 0028025332     PISSN: 09410198     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/BF00227446     Document Type: Review

References (108)

1. Serum lipoprotein(a) concentration in patients undergoing continuous ambulatory peritoneal dialysis
2. Evidence for increased levels of plasminogen activator inhibitor and other fibrinolytic variables in patients with coronary artery disease
3. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels
4. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels
5. Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients
6. Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia
7. A new serum type in man — the Lp-system
8. Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein(a) and that cause lipid accumulation in macrophages
9. Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta
10. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism
11. Genetics of the quantitative Lp(a) lipoprotein trait. III Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation
12. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations
13. A receptor-mediated pathway for cholesterol homeostasis
14. Serum lipoprotein(a) in renal transplant recipients receiving cyclosporin monotherapy
15. Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control
16. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia
17. Complications of the nephrotic syndrome
18. Effect of weight loss on serum lipoprotein(a) concentrations in an obese population
19. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients
20. Status of the coronary arteries in the nephrotic syndrome. Analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated
21. Quantitation and localization of apolipoprotein(a) and B in coronary artery bypass vein grafts resected at re-operation
22. In vitro studies of the interaction of isolated Lp(a) lipoprotein and other serum lipoproteins with glycosaminoglycans
23. Association of levels of lipoprotein(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography
24. Elevated plasma concentrations of lipoprotein(a) in patients with endstage renal disease are not related to the size polymorphism of apolipoprotein(a)
25. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen
26. Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein(a)
27. Solubility, immunochemical, and lipoprotein binding properties of apoB100-apo(a), the protein moiety of lipoprotein(a)
28. Lipoprotein(a) serum concentration in familial combined hyperlipidemia
29. Lipoprotein(a) predicts the risk of thrombogenic complications in nephrotic syndrome
30. Polymorphic forms of human apolipoprotein(a): inheritance and relationship of their molecular weights to plasma levels of lipoprotein(a)
31. Vascular smooth-muscle cell hypertrophy vs hyperplasia. Autocrine transforming growth factor- β1 expression determines growth response to angiotensin II
32. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia
33. Proliferation of human smooth muscle cells promoted by Lipoprotein(a)
34. Familial combined hyperlipidemia workshop
35. Levels of Lipoprotein(a) decline with neomycin and niacin treatment
36. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B
37. Lack of change of lipoprotein(a) concentration with improved glycemic control in subjects with type 11 diabetes
38. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis
39. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction
40. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibriogen and fibrin
41. Studies of Lp(a)-lipoprotein as a quantitative genetic trait
42. Hormonal regulation of serum Lp(a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma
43. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients
44. Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria
45. Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin
46. Changes of genetic apolipoprotein phenotypes caused by liver transplantation
47. Lipoprotein(a) is not a metabolic product of other lipoproteins containing apolipoprotein B
48. Lipoprotein(a) als Marker für arteriosklerotische Veränderungen im Bereich des extrakraniellen Carotissystems bei Patienten mit dialysepflichtiger Niereninsuffizienz
49. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis
50. Atherogenesis in transgenic mice expressing human apolipoprotein(a)
51. The gene for the Lp(a)-specific glycoprotein is closely linked to the gene for plasminogen on chromosome 6
52. Lipoprotein(a) a unique risk factor for atherothrombotic disease
53. Lipoprotein(a), fibrin binding, and plasminogen activation
54. Mechanism of activation of latent recombinant transforming factor β1 by plasmin
55. Heterogeneous lipoprotein(a) size isoforms differ by their interaction with the low density receptor and the low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor
56. The nephrotic syndrome and ischaemic heart disease
57. Lipoprotein(a): structure, properties and possible involvement in thrombogenesis and atherogenesis
58. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations
59. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
60. Lp(a): an interloper into the fibrinolytic system
61. A potential basis for the thrombotic risks associated with lipoprotein(a)
62. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease
63. Estrogen replacement therapy and lipoprotein(a)
64. Linkage disequilibrium of plasminogen polymorphism and assignment of the gene to human chromosome 6826-27
65. The increased risk of coronary heart disease associated with nephrotic syndrome
66. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis
67. Apolipoprotein(a) genetic polymorphism and serum lipoproten(a) concentration in patients with peripheral vascular disease
68. Relation between apo(a) isoforms and Lp(a) density in subjects with different apo(a) phenotype: study before and after a fatty meal
69. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production
70. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients
71. Correlation of apolipoprotein(a) isoproteins with Lp(a) density and distribution in fasting plasma
72. Lipoprotein(a) as a risk factor for myocardial infarction
73. A prospective study of lipoprotein(a) and the risk of myocardial infarction
74. Short-and long-term effects of LDL-apheresis on lipoprotein(a) serum levels
75. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged man
76. Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it
77. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease
78. Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein(a)
79. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age
80. Localisation of apolipoprotein(a) and B-100 in various renal diseases
81. Oxidation of lipoprotein Lp(a). A comparison with low-density lipoproteins
82. Lipoprotein(a): A genetically determined cardiovascular pathogen in search of a function
83. Lipoprotem(a) heterogeneity and biological relevance
84. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia
85. High serum lipoprotein(a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis
86. Serum lipoprotein(a) in men with proteinuria due to idiopathic membranous nephropathy
87. Association of coronary atherosclerosis with hyperapobetalipoproteinemia
88. Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women
89. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level
90. Relationship between apolipoprotein(a) phenotype, lipoprotein(a) concentration in plasma, and low density lipoprotein receptor function in a large kindred with familial hypercholesterolemia due to the Pro664 → Leu mutation in the LDL receptor gene
91. Transforming growth factor-β: Biological function and chemical structure
92. Lipoprotein(a) in patients with proteinuria
93. Lipoprotein(a) binding to other apolipoprotein B containing lipoproteins
94. Interaction of apolipoprotein(a) with apolipoproteinB-containing lipoproteins
95. The mysteries of lipoprotein(a)
96. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma
97. Defects in the low density lipoprotein receptor gene affect lipoprotein(a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis
98. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome
99. Effects of simvastatin on lipoprotein(a) and lipoprotein composition in patients with nephrotic syndrome
100. Does the nephrotic syndrome increase the risk of cardiovascular disease?
101. Lipid and lipoprotein(a) concentrations in renal transplant patients
102. Lipoprotein(a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis
103. Linkage between the loci for the Lp(a) lipoprotein (LP) and plasminogen (PLG)
104. Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population
105. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolemia
106. Interactions of low density lipoprotein2 and other apolipoproteinB-containing lipoproteins with lipoprotein(a)
107. Fluctuations of plasma lipoprotein-a concentrations during pregnancy and post partum
108. Lipoprotein(a) as a strong indicator for cerebrovascular disease